TCGA-B6-A0RM-01A-11R-A084-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.470
- MYC_TARGETS_V2+0.410
- MYC_TARGETS_V1+0.330
- OXIDATIVE_PHOSPHORYLATION+0.290
- ESTROGEN_RESPONSE_EARLY+0.260
- ADIPOGENESIS+0.240
- DNA_REPAIR+0.240
- PEROXISOME+0.190
- FATTY_ACID_METABOLISM+0.180
- E2F_TARGETS+0.170
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- KRAS_SIGNALING_UP-0.480
- ANGIOGENESIS-0.470
- INFLAMMATORY_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.450
- COMPLEMENT-0.420
- CHOLESTEROL_HOMEOSTASIS-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA12-01A-11R-A41B-07 | — | B | 0.871 |
| 2 | TCGA-F7-A61V-01A-11R-A28V-07 | — | — | 0.859 |
| 3 | R16 | — | — | 0.837 |
| 4 | BS_NKEAAFMW | medulloblastoma | — | 0.835 |
| 5 | TCGA-AC-A6NO-01A-12R-A33J-07 | — | B | 0.834 |
| 6 | TCGA-EW-A1P6-01A-11R-A144-07 | — | A | 0.833 |
| 7 | BSR_15_0056_E1_S102 | — | B | 0.828 |
| 8 | TCGA-B6-A0IC-01A-11R-A034-07 | — | B | 0.827 |
| 9 | 20120289.LumB | — | B | 0.826 |
| 10 | TCGA-BH-A0H0-01A-11R-A056-07 | — | B | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |